Normophthal for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L / Opus 5.5

Also known as: Normoftal, Normophtal, AKS-G, Lys-Glu, KE, Lysylglutamic Acid, Lysylglutamate, Vilon, AB-0 Peptide

Motivation

Normophthal (also sold as Normoftal) is a Russian dietary supplement in capsule form that contains a very short synthetic peptide built from two amino acids, lysine and glutamic acid. It belongs to a family of “peptide bioregulators” created at the St. Petersburg Institute of Bioregulation and Gerontology and is marketed to support the light-sensing tissue at the back of the eye. The central idea is that the peptide acts as a signal that returns gene activity in aging eye cells toward a more youthful pattern.

Interest comes from two directions. Eye diseases that erode sight with age, such as macular degeneration and glaucoma, remain hard to halt, and an oral supplement meant to protect eye tissue appeals to people planning for decades of good vision. The same peptide has also been studied in animals for effects on aging, drawing attention from the longevity community.

This review examines what is known about Normophthal: how it is proposed to work, the human and laboratory evidence on benefits and risks, how it is used in practice, and how much of that evidence comes from the people who developed and sell it.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Vilon

Dedicated article on Vilon, the lysine–glutamic acid dipeptide in Normophthal, summarizing its proposed gene-regulating mechanism, injected dosing, animal toxicity data, a tumor signal in cancer-prone mice and absent Western regulatory approval.

Examine

No Examine article on Normophthal exists.

ConsumerLab

No ConsumerLab article on Normophthal exists.

Systematic Reviews

This section lists the only systematic review covering Normophthal’s active dipeptide, a mechanistic review by its developers, plus one meta-analysis on the proven eye treatment that Normophthal could displace.

Peptide Regulation of Gene Expression: A Systematic Review - Khavinson et al., 2021

Developers’ review of short-peptide gene regulation, including the lysine–glutamic acid dipeptide’s DNA binding; mechanistic only, with no clinical outcomes or safety data.
Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials - Maier et al., 2005

Meta-analysis of randomized trials showing pressure-lowering treatment delays visual field loss in glaucoma; it quantifies the benefit forgone if Normophthal replaces proven care.

No systematic review or meta-analysis addresses Normophthal’s own clinical effects, so the claimed eye benefit is not represented by a review; the principal risk, displacing proven eye treatment, is represented only through the forgone benefit above.

Mechanism of Action

Normophthal’s listed active ingredient is a synthetic peptide coded “AKS-G” and described as lysine plus glutamic acid. The U.S. National Library of Medicine’s MeSH (Medical Subject Headings) vocabulary files Normophthal under lysylglutamic acid, the dipeptide also sold as Vilon. Each capsule carries about 100 μg of peptide.

Developers’ model: according to the institute that co-produces Normophthal, very short peptides are said to enter cell nuclei, bind specific DNA sequences and histones (proteins that spool DNA), and switch age-silenced genes back on. In embryonic retinal cell cultures the dipeptide increased maturation markers of neurons and of the retinal pigment epithelium (the support layer beneath the light-sensing cells) (Khavinson et al., 2013); in stem cells it shifted expression of aging-related genes (Ashapkin et al., 2020).
Competing view: an oral dipeptide is expected to be split into free lysine and glutamate by peptidases (protein-cutting enzymes) in the gut and blood, leaving little intact peptide to reach the eye. Intact uptake would depend on PEPT1 (an intestinal transporter for small peptides) (Wang et al., 2017). Sequence-specific DNA binding has not been confirmed by independent laboratories.
Pharmacology: no human pharmacokinetic (absorption and clearance) study exists, so half-life, tissue distribution and oral bioavailability are unknown. Metabolism is splitting by peptidases into two dietary amino acids; involvement of CYP enzymes (cytochrome P450, the liver’s main drug-processing enzymes) is not expected. Claimed selectivity for eye tissue rests on the developers’ cell-culture and transporter modeling work (Khavinson et al., 2022).

Historical Context & Evolution

Normophthal grew out of Soviet military medicine. From the 1970s, Vladimir Khavinson’s team at the Kirov Military Medical Academy extracted polypeptide mixtures (chains of many amino acids) from animal organs, including a calf-retina extract later registered in Russia as the injectable drug Retinalamin. Its original intended use was restoring retinal function in eye disease and injury. After the St. Petersburg Institute of Bioregulation and Gerontology was founded in 1992, the group analyzed the amino acid make-up of such extracts and synthesized ultrashort peptides meant to reproduce them. The lysine–glutamic acid dipeptide was first developed as the immune-adjusting agent Vilon and later marketed, for the eye, as the dietary supplement Normophthal.

Its move into health optimization came through the developers’ “peptide theory of aging”, advanced by the same institute that profits from the resulting supplements, which holds that falling levels of tissue-specific peptides drive organ aging and that supplying them restores function (Khavinson, 2002). Female mice given injected Vilon lived longer, stayed more active and developed fewer spontaneous tumors (Khavinson et al., 2000), and controlled series with related retinal peptides reported better vision in retinal degeneration (Khavinson et al., 2002).

Outside Russia, the work has been neither confirmed nor refuted. Almost all findings come from one research network, using small, mostly unblinded designs. What has changed recently is the arrival of Italian and Georgian collaborators running cell-culture studies; independent controlled human trials with standard retinal imaging have not yet appeared.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human data on Normophthal come from one small trial with no reported blinding, and no outcome has been replicated in a second controlled trial.

Medium 🟩 🟩

Retinal Function in Early Degenerative Retinal Disease

In a 2008 randomized add-on trial, 28 adults aged 48–68 had retinal dystrophies (progressive degeneration of retinal cells); adding Normophthal to standard care for 20–30 days was followed by larger electroretinogram (the retina’s electrical response to light) amplitudes than standard care alone, with acuity and visual-field gains mostly in early-stage disease (manufacturer trial report). Only electroretinogram values are shown per group, tested against baseline, not between groups; the report describes no blinding, is not peer-reviewed and comes from the product’s co-producer. Retinal cell cultures support plausibility (Khavinson et al., 2013).

Magnitude: Electroretinogram b-wave (the inner retina’s response) amplitude rose from 118 μV to 211 μV with Normophthal versus 187 μV with standard care alone (normal 225–400 μV); the a-wave (the light-sensing cells’ response) rose from 20.5 μV to 28.4 μV versus 24.2 μV.

Corneal Recovery After Injury or Eye Surgery

In the same randomized trial’s corneal subgroup (20 adults with post-injury corneal degeneration, 11 given Normophthal and 9 standard care alone), developers report 1.3–1.4-fold better treatment results and softer scars (manufacturer trial report). No group-level data are published, and the report describes no blinding. An institute review describes peptide use after eye surgery (Trofimova & Mamedova, 2015).

Magnitude: Blepharospasm (involuntary eyelid squeezing), light sensitivity and tearing resolved about twice as fast as with standard care alone.

Low 🟩

Lower Insulin Requirement in Type 1 Diabetes

Injected Vilon added to standard therapy in adults with type 1 diabetes reduced the insulin dose needed for stable glucose in most patients (Kuznik et al., 2007). This study concerns the injected dipeptide, not oral Normophthal.

Magnitude: Most Vilon-treated adults with type 1 diabetes needed a lower insulin dose; no average reduction is reported in the available abstract.

Better Outcomes After Colorectal Cancer Treatment

In a controlled trial in older adults with stage III rectal or colon cancer, adding Vilon to surgery, radiotherapy and chemotherapy was reported to improve 2-year survival and reduce postoperative complications (Ias’kevich et al., 2005). Khavinson co-authored the report, which calls results preliminary; it tested Vilon, not oral Normophthal.

Magnitude: 2-year survival rose and postoperative complications fell when Vilon was added to combined treatment in older adults with stage III colorectal cancer; the literature reports no outcome figure.

Speculative 🟨

Slowing Glaucoma, Cataract and Macular Degeneration

Distributors market Normophthal for glaucoma, cataract and age-related macular degeneration, but no study has reported outcomes in these conditions. Basis is vendor claims and retinal cell cultures only (Khavinson et al., 2013).

Longer Lifespan and Fewer Spontaneous Tumors ⚠️ Conflicted

Injected Vilon lengthened lifespan and reduced spontaneous tumors in normal female mice (Khavinson et al., 2000) but increased multiple tumors in cancer-prone mice (Alimova et al., 2002). Animal data only. Net reading: tumor direction unresolved.

Reactivation of Age-Silenced Genes

In lymphocytes (white blood cells) from older adults, the dipeptide loosened compacted chromatin (packaged genetic material) and reactivated ribosomal genes (genes for the cell’s protein factories) (Lezhava et al., 2004). Basis is cell culture only.

Immune Modulation

In human immune-cell cultures, Vilon reduced release of the inflammatory messengers TNF (tumor necrosis factor) and IL-6 (interleukin-6) (Avolio et al., 2022). Basis is cell culture only.

Reduced Clotting Tendency in Type 1 Diabetes

In a randomized trial in type 1 diabetes, injected Vilon raised the body’s own clot-preventing proteins (antithrombin III, protein C) and clot breakdown (Kuznik et al., 2006). Basis is clotting markers only, not clinical events.

Digestive Enzyme Activity in the Aging Gut

Oral Vilon raised digestive enzyme activity in older rats, narrowing age differences (Khavinson et al., 2001). Basis is animal data only, though notable as oral-route evidence.

Benefit-Modifying Factors

Genetic variation: No pharmacogenetic (gene-guided drug response) studies exist. Variants in SLC15A1 (the gene encoding the PEPT1 transporter) could in theory alter uptake of any intact dipeptide; inherited retinal dystrophies differ by gene, and the trial did not report genotypes.
Baseline retinal function: The trial reported the largest gains in early-stage disease, when electroretinogram amplitudes were reduced but still measurable (manufacturer trial report); advanced tissue loss leaves little responsive retina.
Sex: The treated arm enrolled 15 men and 14 women, and no sex-specific results were reported (manufacturer trial report); no sex differences in benefit are documented.
Pre-existing conditions: Benefits were studied only as add-ons in retinal dystrophy, post-injury corneal disease and, for Vilon, type 1 diabetes and colorectal cancer. No data exist in healthy eyes, so preventive use rests on extrapolation.
Age: Participants were 35–68; no data exist beyond 70, where macular degeneration (age-related loss of central vision) is most common and more advanced tissue loss could blunt effects.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data consist of one small trial with no reported blinding and manufacturer labeling, which report no side effects, with no replicated human trials.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or consistent observational dataset has documented a specific adverse event from Normophthal or its dipeptide.

Low 🟥

Delayed Proven Treatment for Sight-Threatening Disease

Using Normophthal instead of pressure-lowering therapy for glaucoma (optic nerve damage) or anti-VEGF injections (drugs blocking leaky vessel growth) for wet macular degeneration risks permanent vision loss. Evidence is indirect, from trials of proven treatments (Heijl et al., 2002).

Magnitude: In the Early Manifest Glaucoma Trial, untreated early glaucoma progressed in 62% of patients over about 6 years versus 45% with pressure-lowering treatment.

Excipient Intolerance

Capsule excipients (inactive ingredients) include lactose, beet sugar, starch and polysorbate 80 (an emulsifier); intolerance to components is a labeled contraindication (RLS drug-register monograph). Most lactose-intolerant people tolerate such small amounts (Mill et al., 2018).

Magnitude: Not quantified in available studies. No trial has reported intolerance rates for Normophthal’s capsule ingredients.

Low Blood Sugar When Combined With Insulin

Injected Vilon lowered insulin requirements in type 1 diabetes (Kuznik et al., 2007); without dose adjustment, this could cause hypoglycemia (low blood sugar). Transfer of this effect to oral Normophthal is unproven.

Magnitude: Insulin needs fell in most Vilon-treated type 1 diabetes patients, but no dose figure is reported (Kuznik et al., 2007), so hypoglycemia becomes likelier when insulin doses are not adjusted; the literature reports no hypoglycemia rate.

Speculative 🟨

Tumor Promotion in Susceptible Tissue ⚠️ Conflicted

In cancer-prone HER2 (a growth-signal receptor) mice, Vilon raised multiple mammary tumors to 95% versus 75% (Alimova et al., 2002); other rodent studies showed fewer tumors. Net reading: the direction of effect remains unresolved.

Immune Overstimulation in Autoimmune Disease

The dipeptide pushes immature T cells (immune cells that direct attacks) toward helper-cell maturation in culture (Sevostianova et al., 2013). Basis is mechanistic only; no human reports exist.

Risk-Modifying Factors

Genetic variation: No pharmacogenetic data exist. Peptidases, not CYP enzymes, break the dipeptide down, so common drug-metabolism variants are not expected to matter; inherited cancer-risk variants such as BRCA1/2 (DNA-repair genes) bear only on the speculative tumor signal.
Baseline biomarkers: In type 1 diabetes, an HbA1c (average blood sugar over three months) already near target leaves the least margin if insulin needs fall, raising hypoglycemia risk.
Sex: No sex differences in adverse events are documented. The tumor signal arose in female mice with mammary tumors, so women with prior breast cancer carry the relevant, though speculative, exposure.
Pre-existing conditions: Active cancer, autoimmune disease, galactosemia (inherited inability to process milk sugar) and severe lactose intolerance raise theoretical or ingredient-related risk; glaucoma or wet macular degeneration raise the stakes of delaying standard care.
Age: Adults over 70 have the highest rates of macular degeneration and glaucoma, so substitution for proven care costs most there; no age-specific tolerability data exist.

Key Interactions & Contraindications

Insulin and sulfonylureas (drugs that make the pancreas release insulin, e.g., gliclazide, glimepiride): Monitor. Injected dipeptide lowered insulin needs (Kuznik et al., 2007); additive glucose lowering could cause hypoglycemia. More frequent glucose checks during a first course and prescriber-guided dose adjustment are the usual mitigations.
Cytotoxic chemotherapy (cell-killing cancer drugs; cyclophosphamide): Caution. In tumor-bearing mice, Vilon given simultaneously with cyclophosphamide shortened survival, whereas Vilon alone prolonged it (Barykina et al., 2003). Separating courses from chemotherapy cycles is the authors’ proposed mitigation.
Anticoagulants and antiplatelet drugs (blood thinners; warfarin, apixaban, clopidogrel): Monitor (theoretical). Vilon raised natural anticoagulants and fibrinolysis (clot breakdown) in diabetes (Kuznik et al., 2006); extra bleeding is possible but unreported. Rechecking INR (international normalized ratio, a clotting test) after 1–2 weeks suits warfarin users.
Immunosuppressants (drugs that dampen immunity; tacrolimus, methotrexate, prednisone): Caution (theoretical). The dipeptide promotes T-cell maturation in culture (Sevostianova et al., 2013), which could oppose intended immunosuppression after transplant or in autoimmune disease; no human reports exist. Avoiding use during transplant immunosuppression is the conservative option.
Over-the-counter drugs (aspirin, ibuprofen, antacids): No documented interactions. Low-dose aspirin shares the theoretical bleeding concern above, so bruising is worth watching; antacids and proton pump inhibitors (stomach-acid reducers, e.g., omeprazole) are not expected to change peptide breakdown.
Supplements with additive anticoagulant or antiplatelet effects (fish oil, ginkgo, high-dose vitamin E): Monitor (theoretical). Combined with the dipeptide’s reported clot-dissolving shift, bleeding tendency could add up. Watching for bruising or nosebleeds and pausing 7 days before surgery limits this.
Supplements with additive glucose-lowering effects (berberine, chromium, alpha-lipoic acid): Monitor in insulin users; additive hypoglycemia is possible. More frequent glucose checks during combined first courses is the mitigation.
Other Khavinson peptides (Visoluten, Epitalon, Retinalamin): No known interaction; the manufacturer pairs Normophthal with Visoluten sequentially. No safety data exist for stacking, which compounds exposure to the speculative tumor signal. Sequential rather than simultaneous courses match the manufacturer’s scheme.
Standard eye treatments (anti-VEGF injections such as aflibercept or ranibizumab, pressure-lowering drops such as latanoprost, eye surgery): No pharmacological interaction known; the trial used Normophthal only as an add-on. The consequence to avoid is substitution, not combination; keeping scheduled treatment prevents vision loss.

Populations who should avoid Normophthal:

Pregnant or breastfeeding women (labeled contraindication)
Children and adolescents under 18 years (not studied)
People with intolerance to capsule components, including galactosemia
People with active cancer, during chemotherapy cycles, or with a history of HER2-positive breast cancer (precautionary, based on animal data)
Solid-organ transplant recipients on maintenance immunosuppression (theoretical immune stimulation)
People with type 1 diabetes and a history of level 3 hypoglycemia (a severe episode requiring another person’s help), unless glucose is continuously monitored

Risk Mitigation Strategies

Continued standard eye care: Continuing prescribed drops or injections and eye examinations every 6–12 months, or as the specialist schedules, prevents irreversible vision loss from delayed proven treatment.
Tighter glucose monitoring on insulin: Checking glucose at least 4 times daily, or using a continuous glucose monitor, during the first 2–4 weeks of each course catches hypoglycemia from falling insulin needs.
Label check for lactose sensitivity: People reacting to small lactose amounts can take lactase (the enzyme that digests milk sugar) with each dose, and people with galactosemia can skip the product entirely, preventing excipient intolerance.
Cancer-history screen: A history of HER2-positive breast cancer or active malignancy is a reason to forgo use, and courses are kept at least one chemotherapy cycle (typically 3–4 weeks) apart from treatment, limiting the speculative tumor-promotion exposure.
Autoimmune flare tracking: People with autoimmune disease who try it can track symptoms and their usual disease-activity blood tests every 4 weeks, stopping at the first flare to limit theoretical immune overstimulation.

Therapeutic Protocol

Treatment course (manufacturer): 2 capsules (about 200 μg peptide) twice daily with meals for 1 month, repeated after 2–3 months; set by the St. Petersburg institute and distributor Peptide Bio, both earning revenue from sales.
Prevention course (manufacturer): 2 capsules once daily with meals for 1 month, repeated every 4–6 months; the Russian drug-register label gives a broader 1–2 capsules 1–2 times daily.
Trial regimen: The 2008 add-on trial used 1–2 capsules twice daily with food for 20–30 days alongside standard treatment, with repeat courses after 3–6 months as indicated (manufacturer trial report).
Bioregulator approach: Khavinson-lineage practitioners, including ophthalmologist Svetlana Trofimova’s group at the institute, follow a Normophthal course with Visoluten for 1–2 months, sometimes alongside injectable Retinalamin courses.
Conventional approach: American Academy of Ophthalmology guidelines, written by specialists billing for these procedures, use pressure lowering for glaucoma (Gedde et al., 2021) and anti-VEGF injections or AREDS2 vitamins for macular degeneration (Flaxel et al., 2020); no head-to-head comparison exists.
Time of day: No timing studies exist; labels specify morning and evening doses with meals, while some distributors say before meals, a discrepancy left unresolved.
Half-life and split dosing: No human half-life has been measured; free dipeptides are presumed to be broken down quickly, the stated rationale for twice-daily split doses during treatment courses and single daily doses for prevention.
Genetics: No genotype-guided dosing exists; SLC15A1 (PEPT1) variants are a theoretical, untested modifier of uptake.
Sex: No sex-specific dosing is described; the trial enrolled men and women in similar numbers without reporting differences.
Age: The trial covered ages 35–68; no dose adjustment is described for older adults, who were not studied beyond 68.
Baseline biomarkers: Early-stage disease with measurable electroretinogram responses showed the largest gains; baseline visual fields and retinal imaging show whether residual function remains to preserve.
Pre-existing conditions: Retinal dystrophy patients received 1–2 capsules twice daily for 20–30 days, with course length set by disease severity; in diabetes, glucose status shapes monitoring rather than dose.

Discontinuation & Cycling

Short-term, not lifelong: Normophthal is designed for 1-month courses repeated 2–6 times per year, not continuous daily use; there is only one agent, so no staged stopping applies.
Withdrawal effects: None reported; the label and trial describe no dependence or rebound.
Tapering: No taper is described; each course simply ends after 20–30 days.
Cycling: Cycling is built in, with 2–3 month (treatment) or 4–6 month (prevention) gaps; the developers assume effects persist between courses, which has not been tested against continuous dosing.
Stopping signal: Repeat courses are decided after retesting vision; absence of change on retesting is the practical signal the developers use to stop.

Sourcing and Quality

Manufacturers: Two Russian producers appear on labels: “Firma-Vita”, a chemical-biological association affiliated with the Russian Academy of Sciences, and Peptide Bio, which names the St. Petersburg Institute of Bioregulation and Gerontology as co-developer.
Formulation: Capsules of 0.2 g or 0.275 g (60 per pack) and tablets of 0.16 g or 0.3 g; each capsule carries about 100 μg of the lysine–glutamic acid peptide with lactose, beet sugar, starch and polysorbate 80.
What to look for: No independent purity or content assay has been published, and no third-party testing program covers the product. Batch number, 5-year expiry, intact blister packs and storage at 2–25 °C away from light are the checkable quality markers.
Counterfeit and gray-market risk: International sales run through online distributors; sealed original packs with Russian labeling and a state registration certificate reduce substitution risk. “Research-grade” Lys-Glu powders are different, unregulated products.
Reputable sources: Russian pharmacies listed in the RLS drug register and distributors naming Peptide Bio or Firma-Vita as supplier are the traceable channels; no compounding pharmacy prepares Normophthal.

Practical Considerations

Time to effect: In the trial, changes were measured after 20–30 days (manufacturer trial report); developers treat the first 1-month course as the assessment window, with repeat courses after 2–6 months.
Common pitfalls: Substituting it for prescribed glaucoma or macular treatment, expecting effects in advanced tissue loss, buying unverified gray-market product, and assuming injected Vilon data apply to oral capsules.
Regulatory status: Registered in Russia as a biologically active food supplement, not a medicine; it holds no approval from the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency), and no health claim is authorized there.
Cost and access: About €69 or 1,000 rubles per 60-capsule pack; hard to obtain outside Russia. Payers reimburse only approved therapies, so have no incentive to evaluate cheap supplements; no drug maker funds trials of a low-cost peptide, structurally biasing research funding and guideline formation.

Interaction with Foundational Habits

Sleep: None documented. No sleep effects are reported for Normophthal; other Khavinson peptides aimed at the pineal gland are marketed for sleep, but this dipeptide has no such data. The labeled evening dose with dinner has no reported insomnia.
Nutrition: Indirect. Labeled dosing is with meals; dietary protein supplies far more lysine and glutamate than the 400 μg daily peptide dose, so any effect cannot be nutritional. Leafy greens (lutein, zeaxanthin) and oily fish support the same retinal goals independently.
Exercise: None documented. No studies examine exercise interactions or performance effects, so timing relative to workouts has no evidence-based rule; training and dosing can be scheduled independently.
Stress management: Indirect, potentiating in animals only. Injected Vilon raised emotional-stress resistance and reduced adrenal enlargement in rats (Koplik et al., 2002); effects on human cortisol or stress response are unstudied.

Monitoring Protocol & Defining Success

Baseline testing: Before a first course, a complete eye examination establishes the reference point: best-corrected visual acuity, automated visual fields, eye pressure, OCT (optical coherence tomography, a light-based retinal scan) of the retina and optic nerve, and, where available, a full-field electroretinogram, the functional test used in the Normophthal trial. People on insulin add fasting glucose and HbA1c; warfarin users add an INR.

Ongoing monitoring: Acuity and symptoms are reviewed at the end of each 1-month course, then full eye testing follows every 6–12 months (every 3–6 months with glaucoma or macular degeneration), comparing results on the same devices. Glucose checks are most frequent during the first 2–4 weeks of each course, and INR is rechecked 1–2 weeks after starting.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Best-corrected visual acuity	20/20 (logMAR 0.0) or better	Central vision	logMAR = logarithm of the minimum angle of resolution, a chart score; conventional practice often accepts 20/25; same chart and lighting each visit
Visual field mean deviation	0 to −2 dB; track change from own baseline	Peripheral vision loss	dB = decibels; automated perimetry (machine-based visual field testing); two baseline tests offset the learning effect
Intraocular pressure	10–18 mmHg	Glaucoma risk	Conventional reference 10–21 mmHg; pressure peaks in early morning, so measure at a consistent time
OCT nerve fiber layer and macular thickness	No established target; track change from own baseline	Structural retinal loss	Same device and software for every comparison
Full-field electroretinogram (a- and b-wave)	a-wave 30–60 μV; b-wave 225–400 μV	The only functional endpoint in the Normophthal trial	Laboratory-specific norms; 20–30 minutes of dark adaptation before testing
Fasting glucose	75–90 mg/dL	Glucose-lowering interaction	Conventional reference 70–99 mg/dL; 8–12 hour fast
HbA1c	4.8–5.4% without diabetes; individual target on insulin	Hypoglycemia risk and glucose trend	Conventional non-diabetic cutoff below 5.7%; pair with continuous glucose data on insulin
INR (warfarin users only)	Individual therapeutic target, commonly 2.0–3.0	Bleeding interaction	Recheck 1–2 weeks after starting a course

Qualitative markers:

Night vision and adaptation to darkness
Glare and contrast in daily tasks such as reading and night driving
Eye comfort: light sensitivity, tearing, dryness
Digestive tolerance, such as bloating from the lactose excipient
Unusual bruising or nosebleeds in people on anticoagulants or antiplatelet drugs

Emerging Research

No registered trials: A ClinicalTrials.gov search (September 2026) for Normophthal, Normoftal, Vilon, Lys-Glu and Khavinson peptide bioregulators found no registered studies, so no NCT (National Clinical Trial) identifier exists and no independent trial is under way.
Retinal cell work with Italian collaborators: An Italian team co-authored by Khavinson and institute staff found that Epitalon, a related Khavinson retinal peptide, restored wound healing in high-glucose-damaged retinal pigment cells (Gatta et al., 2025); the same model could test the lysine–glutamic acid dipeptide directly.
Aging-gene targets: Mapping of the dipeptide’s sequence motif across the human proteome (the full set of human proteins) (Terekhov et al., 2020) and its effects on aging genes in stem cells (Ashapkin et al., 2020) propose testable targets whose replication would strengthen or weaken the mechanism.
Chromatin in older adults: Tbilisi researchers extended Vilon chromatin work in lymphocytes from 75–88-year-olds (Lezhava et al., 2023); whether this occurs in living older adults taking capsules remains untested.
Tumor-safety question: The finding of more multiple tumors with Vilon in cancer-prone mice (Alimova et al., 2002) has never been revisited; long-term testing for cancer-causing potential would either retire or confirm this signal and could weaken the case.
Oral bioavailability: Whether intact Lys-Glu reaches the blood after oral dosing is unmeasured; the developers’ transporter review (Khavinson et al., 2022) outlines PEPT1 and LAT1 (an amino acid transporter) routes, and a human pharmacokinetic study would settle whether capsule use can build on injection data.

Conclusion

Normophthal is a Russian capsule supplement carrying a tiny two-amino-acid peptide, the same molecule sold as Vilon, promoted to support the retina and, by extension, healthy aging. Its rationale is the claim that very short peptides can reset gene activity in aging tissue, an idea its developers have pursued for decades but that outside laboratories have not confirmed.

For adults focused on keeping their sight for the long term, the most relevant evidence is one small controlled study in which adding Normophthal to standard care was linked to better retinal function in early-stage retinal degeneration, with a less documented signal for healing of the eye’s surface. Longer life, reawakened genes and calmer immune signaling come only from animal and cell studies, many of which used injections rather than capsules.

No side effects were reported, but safety data are thin. The main practical risk is letting the supplement replace proven treatment for glaucoma or macular degeneration. Smaller concerns are lower blood sugar in insulin users, intolerance of capsule ingredients, and an unresolved tumor signal in one strain of cancer-prone mice.

Nearly all evidence comes from the institute that developed the product and shares in its production, and from its commercial partners, so a financial conflict of interest runs through the evidence base. Guidelines for the proven eye treatments are likewise written by specialists paid to deliver them. Whether the peptide survives digestion is unknown. Taken together, Normophthal is an inexpensive, apparently well-tolerated add-on whose benefits remain uncertain and largely unverified.

Top - Benefits - Risks - Protocol

Normophthal for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Retinal Function in Early Degenerative Retinal Disease

Corneal Recovery After Injury or Eye Surgery

Low 🟩

Lower Insulin Requirement in Type 1 Diabetes

Better Outcomes After Colorectal Cancer Treatment

Speculative 🟨

Slowing Glaucoma, Cataract and Macular Degeneration

Longer Lifespan and Fewer Spontaneous Tumors ⚠️ Conflicted

Reactivation of Age-Silenced Genes

Immune Modulation

Reduced Clotting Tendency in Type 1 Diabetes

Digestive Enzyme Activity in the Aging Gut

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Delayed Proven Treatment for Sight-Threatening Disease

Excipient Intolerance

Low Blood Sugar When Combined With Insulin

Speculative 🟨

Tumor Promotion in Susceptible Tissue ⚠️ Conflicted

Immune Overstimulation in Autoimmune Disease

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion